Evidence map›Paper›PMID 41469306›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study.

Joo-Yeon Lee, Don Gueu Park, Joohon Sung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joo-Yeon LeeInstitute of Health and Environments, Seoul National University, Seoul, 08826, South Korea.
Don Gueu ParkAjou University School of Medicine, Suwon, Gyeonggi-do, 16499, South Korea.
Joohon SungInstitute of Health and Environments, Seoul National University, Seoul, 08826, South Korea; Department of Epidemiology, Graduate School of Public Health, Seoul National University, Seoul, 08826, South Korea; Genome Medicine Institute, Seoul National University Medical Research Center, 03080 Seoul, South Korea. Electronic address: jsung@snu.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) remains without effective disease-modifying therapies, primarily due to limited understanding of its underlying mechanisms. Emerging evidence suggests that dipeptidyl peptidase-4 inhibitors (DPP-4Is), commonly used as anti-diabetics, may offer neuroprotective effects. We aimed to evaluate the potential of repurposing DPP-4Is for reducing the PD risk, using a drug-target Mendelian randomization (MR) approach, with specific attention to sex. We performed two-sample MR analyses using instrumental variables (IVs) for DPP-4Is derived from gene expression quantitative trait loci (IV

Indexed as

Dipeptidyl-Peptidase IV InhibitorsDrug RepositioningMendelian Randomization AnalysisParkinson DiseaseFemaleGenome-Wide Association StudyHumansMaleQuantitative Trait LociDipeptidyl-Peptidase IV InhibitorsDipeptidyl peptidase-4 inhibitorDrug repurposingMendelian randomizationParkinson's disease

Identifiers

PMID41469306
PMCPMC12976525

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.